Chronic kidney disease, stage 5
Methodology & AI Transparency ⓘ
Chronic kidney disease, stage 5 Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as N18.5, Chronic kidney disease, stage 5 falls under Kidney & Renal management, where spot urine albumin-to-creatinine in Chronic kidney disease, stage 5 (N18.5: ratio) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry N18.5: Chronic kidney disease, stage 5 is managed within Kidney & Renal.
- 3 Typical cash cost range: Primary evaluation for Chronic kidney disease, stage 5 incorporates spot urine albumin-to-creatinine in Chronic kidney disease, stage 5 (N18.5: ratio) and symptom diary review.
- 4 Top reported side effects / signs: Key Kidney & Renal biomarkers for Chronic kidney disease, stage 5 (N18.5): Serum Potassium, Bicarbonate in Chronic kidney disease, stage 5 (N18.5: & Phosphorus) & eGFR (Creatinine + in Chronic kidney disease, stage 5 (N18.5: Cystatin C)) (>= 90 mL/min/1.73m2 (N18.5)).
Ask our AI Specialists anything about Chronic kidney disease, stage 5
What Is Chronic kidney disease, stage 5?
Designated in federal medical registries as N18.5, Chronic kidney disease, stage 5 falls under Kidney & Renal management, where spot urine albumin-to-creatinine in Chronic kidney disease, stage 5 (N18.5: ratio) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Chronic kidney disease, stage 5 (N18.5, Kidney & Renal) reflects disordered calcium-phosphate-PTH mineral in Chronic kidney disease, stage 5 (N18.5: metabolism). longitudinal control is benchmarked via Serum Potassium, Bicarbonate in Chronic kidney disease, stage 5 (N18.5: & Phosphorus).
Common Symptoms & Clinical Signs
- • Presentation of Chronic kidney disease, stage 5 (N18.5): fluid retention in in Chronic kidney disease, stage 5 (N18.5: ankles, hands, or)
- • Secondary Chronic kidney disease, stage 5 clinical sign: fatigue, muscle cramps, in Chronic kidney disease, stage 5 (N18.5: metallic taste, or)
- • Symptom flares in Chronic kidney disease, stage 5 correlating with Serum Potassium, Bicarbonate in Chronic kidney disease, stage 5 (N18.5: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N18.5)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Chronic kidney disease, stage 5 (N18.5: ratio) evaluation (N18.5)
Chronic kidney disease, stage 5 Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N18.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Chronic kidney disease, stage 5 (N18.5: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N18.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Chronic kidney disease, stage 5 (N18.5: Cystatin C)) | >= 90 mL/min/1.73m2 (N18.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Chronic kidney disease, stage 5 (N18.5: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N18.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic kidney disease, stage 5
Treatment selection for Chronic kidney disease, stage 5 depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic kidney disease, stage 5)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Atorvastatin and rosuvastatin on kidney: What a 29,147-Participant Study Found A and R show similar reno-protective effects in patients at high heart and blood vessel risk, with comparable rates of new onset proteinuria when commonly used doses are considered. International journal of cardiology • 2013-09-10 • Meta-Analysis | N = 29,147 | 99/100 | PMID 22633671 ↗ |
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
Chronic kidney disease, stage 5 Patient Community & “People Like Me” Threads
Filter Chronic kidney disease, stage 5 community threads and patient logs by age, biological sex, dosage, and treatment duration.